RICHLAND, WA–(Marketwired – Apr 8, 2015) - IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 9-11, 2015 in Orlando, Florida.
IsoRay CEO Dwight Babcock, commented, “IsoRay is pleased to again participate at the ABS annual meeting. At this meeting, major institution representatives will speak about their experiences and success in treating aggressive cancers, as well as treatment planning methods, using IsoRay’s Cesium-131 isotope. They include the University of Pittsburg Medical Center (UPMC), Sidney Kimmel Medical College at Thomas Jefferson University, University of Kentucky and Tufts University School of Medicine. The four oral presentations at the annual meeting will present results indicating Cesium-131 is an effective treatment modality for incorporation into primary management of gynecologic cancers, demonstrate the lack of significant long-term rectal toxicity following Cesium-131 treatment, discuss the use of FMEA (failure mode effect analysis) to improve the quality of Cesium-131 treatment of head and neck cancer, and provide new insight into the physics associated with Cesium-131 as applied to permanent brain brachytherapy treatment planning . Our participation in many new body sites has IsoRay’s sales team meeting a new and growing mix of medical professionals. This was evidenced by our first participation in the Society of Gynecologic Oncology (SGO) conference two weeks ago, where Dr. Feddock gave a dinner presentation on Cesium-131. With our broader reach and our newly published study results, the medical community has become more aware of the innovative alternative our Cesium-131 products offer patients.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer,lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, future demand for IsoRay’s existing and planned products, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether additional studies will be published or presented with favorable outcomes from treatment with our products, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, whether future studies of treatment of various cancers using our products will have favorable results, whether adoption of our products by medical professionals will continue or grow, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay’s products, changing levels of demand for IsoRay’s current and proposed future products, IsoRay’s ability to reduce or maintain expenses while increasing sales, patient results achieved using our products in both the short and long term, success of future research and development activities, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay’s ability to successfully manufacture, market and sell its products, IsoRay’s ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and marketing efforts, IsoRay’s ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.